Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Champions Oncology stock

Own Champions Oncology stock in just a few minutes.

Champions Oncology, Inc is a biotechnology business based in the US. Champions Oncology shares (CSBR) are listed on the NASDAQ and all prices are listed in US Dollars. Champions Oncology employs 143 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Champions Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CSBR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Champions Oncology share price

Use our graph to track the performance of CSBR stocks over time.

Champions Oncology shares at a glance

Information last updated 2021-04-30.
52-week range$7.05 - $14.68
50-day moving average $11.58
200-day moving average $11.06
Wall St. target price$15.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.09

Buy Champions Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Champions Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Champions Oncology under- or over-valued?

Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Champions Oncology's EBITDA

Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $345,000.

The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.

Champions Oncology financials

Revenue TTM $39.2 million
Gross profit TTM $15.2 million
Return on assets TTM -2.42%
Return on equity TTM -22.29%
Profit margin -3.14%
Book value $0.59
Market capitalisation $150.6 million

TTM: trailing 12 months

Shorting Champions Oncology shares

There are currently 174,078 Champions Oncology shares held short by investors – that's known as Champions Oncology's "short interest". This figure is 9.1% up from 159,598 last month.

There are a few different ways that this level of interest in shorting Champions Oncology shares can be evaluated.

Champions Oncology's "short interest ratio" (SIR)

Champions Oncology's "short interest ratio" (SIR) is the quantity of Champions Oncology shares currently shorted divided by the average quantity of Champions Oncology shares traded daily (recently around 38856.696428571). Champions Oncology's SIR currently stands at 4.48. In other words for every 100,000 Champions Oncology shares traded daily on the market, roughly 4480 shares are currently held short.

However Champions Oncology's short interest can also be evaluated against the total number of Champions Oncology shares, or, against the total number of tradable Champions Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Champions Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Champions Oncology shares in existence, roughly 10 shares are currently held short) or 0.031% of the tradable shares (for every 100,000 tradable Champions Oncology shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Champions Oncology.

Find out more about how you can short Champions Oncology stock.

Champions Oncology share dividends

We're not expecting Champions Oncology to pay a dividend over the next 12 months.

Have Champions Oncology's shares ever split?

Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.

Champions Oncology share price volatility

Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $7.05 up to $14.68. A popular way to gauge a stock's volatility is its "beta".

CSBR.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.2581. This would suggest that Champions Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Champions Oncology overview

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site